New hope for lung cancer: experimental drug HB0025 faces off against standard therapy
NCT ID NCT07383116
First seen Feb 03, 2026 · Last updated May 13, 2026 · Updated 14 times
Summary
This study compares a new drug called HB0025 combined with chemotherapy against the standard treatment (tislelizumab plus chemotherapy) for people with advanced nonsquamous non-small cell lung cancer that cannot be removed by surgery. About 500 adults aged 18 to 75 will receive one of the two combinations every three weeks. The goal is to see which approach works better at delaying cancer growth and improving survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The East Hospital Affiliated to Tongji University
Shanghai, Shanghai 200120, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.